ArticleBMC veterinary research2025
Reverse vaccinology-based identification of immunogenic membrane proteins from zoonotic multidrug-resistant Proteus vulgaris: a one health approach to cross-species vaccine development.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProteus vulgaris is a Gram-negative opportunistic bacterium implicated in wound infections, urinary tract infections, foodborne illnesses, pneumonia and septicemia. It poses a growing threat to human, veterinary and aquaculture health systems. In animals, P. vulgaris has been isolated from cattle, poultry, and pets, while in fish species such as Nile tilapia and Clarias gariepinus, it contributes to ulcerative and systemic diseases. Its frequent detection in raw milk, meat, and retail fish highlights its zoonotic potential. The rise of multidrug-resistant strains across clinical, veterinary, and food sectors underscores the urgent need for alternative control strategies.
resultsThis study employed reverse vaccinology and immunoinformatics to identify potential vaccine targets against P. vulgaris. Candidate proteins were screened based on subcellular localization, antigenicity, allergenicity, toxicity, similarity to human proteins, B- and T-cell epitope binding, immune simulation results, conservation analysis and key physicochemical properties. Seven promising vaccine candidates were identified: Cytochrome bd-I oxidase subunit CydX (A0A094UCZ6), TatA translocase (A0A379F7E9), cytochrome o ubiquinol oxidase subunit IV (KGA56684), hydrogenase maturation factor (A0A379F868), bacteriophage Rz lysis family protein (KGA60362), a lipoprotein (A0A379F4X1) and a hypothetical protein (A0A379F5R5). These targets exhibited strong immunogenic potential, as indicated by immune simulation graphs showing pronounced IFN-γ responses and IgG production.
conclusionThe study supports vaccine development as a viable strategy to combat multidrug-resistant P. vulgaris across species. The identified targets offer promising leads for developing species-specific or cross-protective vaccines applicable in veterinary and aquaculture settings. By addressing veterinary, aquaculture and zoonotic concerns, this research contributes to integrated "One Health" solutions for antimicrobial resistance control and cross-species disease prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.